PPARG and thyroid gland carcinoma: However, the rationale for administration of PPARγ ligands to treat thyroid cancer is not clear as some studies have shown a reduction in PPARγ expression, yet others revealed normal PPARγ expression or the occurrence of PAX8-PPARγ which can inactivate rather than decreasing PPARγ in thyroid cancer (13–19).